Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02875860 · ClinicalTrials.gov registry record · Phase 2
'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial
A Phase 2 study, sponsored by Michael A Belfort.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02875860 is a Phase 2 study that has completed, run by Michael A Belfort. The registered enrollment target is 5 participants.
The verdict
NCT02875860, a Phase 2 study, has completed, sponsored by Michael A Belfort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This trial will test whether temporary fetoscopic endoluminal tracheal occlusion (FETO) rather than expectant management during pregnancy, followed by standardized postnatal management, increases survival at discharge and decreases oxygen need at 6 months in case of survival till discharge.
Interventions
- DEVICE GoldBal2 detachable balloon
- DEVICE Baltaccidbpe100 Delivery Catheter
- OTHER Standardized postnatal care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02875860
The ClinicalTrials.gov registry entry for NCT02875860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael A Belfort, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GoldBal2 detachable balloon is the first listed.
NCT02875860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02875860 about?
NCT02875860 is a clinical study titled "'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial". This trial will test whether temporary fetoscopic endoluminal tracheal occlusion (FETO) rather than expectant management during pregnancy, followed by standardized postnatal management, increases survival at discharge and decreases oxygen need at 6 months in case of survival till discharge.
What is the current status of trial NCT02875860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-01. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02875860?
The interventions under investigation include: GoldBal2 detachable balloon (DEVICE), Baltaccidbpe100 Delivery Catheter (DEVICE), Standardized postnatal care (OTHER).
Who is sponsoring clinical trial NCT02875860?
This trial is sponsored by Michael A Belfort, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.